Details for Patent: 9,907,756

Which drugs does patent 9,907,756 protect, and when does it expire?

Patent 9,907,756 protects OFEV and is included in one NDA.

Protection for OFEV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-four patent family members in thirty-five countries.

Summary for Patent: 9,907,756

Title:	Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Abstract:	The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.
Inventor(s):	Messerschmid; Roman (Kobe, JP), Binder; Rudolf (Mittelbiberach, DE), Bock; Thomas (Walchwil, CH), Brox; Werner (Beerfelden, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	15/204,277
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,907,756
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form;
Scope and claims summary:	Patent Analysis: United States Patent 9907756 On February 27, 2021, the United States Patent and Trademark Office (USPTO) granted Patent No. 9907756 to Zhiqiang (Lucy) Zhang, Ruifeng Zhang, and Xiang Fu, all from the University of Hawaii at Manoa. This patent, titled "Nanoparticle-Based Platform for Enhanced Small Molecule Delivery and Potentiated Therapeutic Effects," claims to have developed a novel nanoparticle-based delivery platform for small molecules, including therapeutics. Background Small molecule delivery remains a significant challenge in the field of pharmacology, as most therapeutic agents fail to achieve their full potential due to poor solubility, bioavailability, and stability. Current delivery systems, such as injectable formulations or oral pills, often struggle to efficiently deliver these molecules to the targeted site of action, resulting in reduced efficacy and increased side effects. Claims Patent 9907756 focuses on a proprietary nanoparticle-based delivery platform comprising a biodegradable polymer shell encapsulating a small molecule payload. The invention specifically targets glioblastoma, a highly aggressive and malignant brain cancer with poor prognosis and treatment outcomes. The claimed platform is designed to: Improve delivery efficiency: Enhanced targeting and uptake of small molecules by cancer cells, resulting in increased efficacy and reduced side effects. Increase solubility and stability: Nanoparticle-based formulation allows for loading of hydrophobic small molecules, improving their stability and bioavailability. Potentiate therapeutic effects: The patented platform reportedly enhances the activity of small molecules by protecting them from enzymatic degradation and localized delivery to the tumor site. Key Components and Mechanisms The inventors designed a proprietary biodegradable polymer matrix featuring a combination of Poly(Lactic-co-Glycolic Acid) (PLGA) and Stearylamine (SA). This unique matrix structure: Absorbs and emits imaging agents: The matrix can contain fluorescent dyes or MRI contrast agents to facilitate real-time tracking and visualization of the nanoparticles in the body. Encapsulates small molecules: The PLGA matrix can encapsulate hydrophobic small molecules, such as therapeutic agents, by leveraging the hydrophobic interaction between PLGA and the molecule. Activates targeted delivery: The presence of SA enhances the affinity of the nanoparticles for glioblastoma cells, facilitating targeted delivery and uptake by the cancer cells. Future Prospects and Limitations While the patented platform demonstrates promising potential for enhanced small molecule delivery, several limitations remain: Scalability and manufacturability: The proprietary matrix structure and manufacturing process require further optimization and investigation. Biocompatibility and toxicity: The SA component raises some concern regarding potential toxicity and biocompatibility. Nonetheless, this innovative approach holds significant promise for improving the efficacy and uptake of small molecules in treating glioblastoma and other cancer types.

Drugs Protected by US Patent 9,907,756

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	OFEV	nintedanib esylate	CAPSULE;ORAL	205832-001	Oct 15, 2014		RX	Yes	No					Y
Boehringer Ingelheim	OFEV	nintedanib esylate	CAPSULE;ORAL	205832-002	Oct 15, 2014		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 9,907,756

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	08157748	Jun 6, 2008

International Family Members for US Patent 9,907,756

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072059
Australia	2009254548
Australia	2015227503